Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Ocaña

Showing results (1-10 of 170) with videos related to

Pageof 17
Sort By:
Molecular Cancer|July 31, 2010
Personalized therapies in the cancer "omics" eraAlberto Ocaña, Atanasio Pandiella
Current Pharmaceutical Design|September 15, 2012
Targeting HER receptors in cancerAlberto Ocaña, Atanasio Pandiella
Cancer Treatment Reviews|September 8, 2009
Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directionsAlberto Ocaña, Eitan Amir
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2008
Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted optionsAlberto Ocaña, Atanasio Pandiella
Cancers|August 14, 2020
Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian CancerAranzazu Manzano, Alberto Ocaña
Journal of Experimental & Clinical Cancer Research : CR|September 16, 2020
Proteolysis targeting chimeras (PROTACs) in cancer therapyAlberto Ocaña, Atanasio Pandiella
Breast Cancer Research : BCR|February 2, 2020
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugatesAlberto Ocaña, Eitan Amir, Atanasio Pandiella
Oncotarget|August 31, 2018
Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial resultsAlberto Ocaña, Eitan Amir, Atanasio Pandiella
Oncotarget|October 21, 2017
BET inhibitors as novel therapeutic agents in breast cancerAlberto Ocaña, Cristina Nieto-Jiménez, Atanasio Pandiella
Oncoscience|September 2, 2015
Erratum: Achilles' heel of triple negative cancerAlberto Ocaña, Juan C Montero, Atanasio Pandiella
Pageof 17

Showing results (1-10 of 170) with videos related to

Sort By:
Pageof 17
Molecular Cancer|July 31, 2010
Personalized therapies in the cancer "omics" eraAlberto Ocaña, Atanasio Pandiella
Current Pharmaceutical Design|September 15, 2012
Targeting HER receptors in cancerAlberto Ocaña, Atanasio Pandiella
Cancer Treatment Reviews|September 8, 2009
Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directionsAlberto Ocaña, Eitan Amir
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2008
Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted optionsAlberto Ocaña, Atanasio Pandiella
Cancers|August 14, 2020
Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian CancerAranzazu Manzano, Alberto Ocaña
Journal of Experimental & Clinical Cancer Research : CR|September 16, 2020
Proteolysis targeting chimeras (PROTACs) in cancer therapyAlberto Ocaña, Atanasio Pandiella
Breast Cancer Research : BCR|February 2, 2020
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugatesAlberto Ocaña, Eitan Amir, Atanasio Pandiella
Oncotarget|August 31, 2018
Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial resultsAlberto Ocaña, Eitan Amir, Atanasio Pandiella
Oncotarget|October 21, 2017
BET inhibitors as novel therapeutic agents in breast cancerAlberto Ocaña, Cristina Nieto-Jiménez, Atanasio Pandiella
Oncoscience|September 2, 2015
Erratum: Achilles' heel of triple negative cancerAlberto Ocaña, Juan C Montero, Atanasio Pandiella
Pageof 17